Related Experiment Video

Updated: Apr 24, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.2K

Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion

Panagiotis Kratimenos1, Ioannis Koutroulis, Dante Marconi

  • 1Drexel University College of Medicine, St. Christopher's Hospital for Children, Neonatal-Perinatal Medicine , 3601 A St., Philadelphia, PA 19134 , USA +1 215 762 7515 ; Pkratimenos@DrexelMed.edu.

Expert Opinion on Therapeutic Targets
|September 6, 2014
PubMed
Abstract

Insights

The FAK-Src-Paxillin complex is overexpressed in neuroblastoma (NB), a childhood cancer. Inhibiting this complex may suppress tumors and prevent metastasis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cellular Biology

Background:

  • Nonreceptor tyrosine kinases are crucial to the integrin system, forming protein complexes at focal adhesions.
  • The focal adhesion kinase (FAK)-Src-paxillin complex mediates cell migration and motility.
  • This complex is overexpressed in advanced neuroblastoma (NB), a pediatric cancer with poor prognosis.

Purpose of the Study:

  • To review recent data on the FAK-Src-paxillin complex in NB.
  • To explore its molecular structure, regulation, and interactions.
  • To assess its potential as a biomarker and therapeutic target in NB.

Main Methods:

  • Literature review of recent scientific data.
  • Analysis of molecular structures and regulatory mechanisms.
  • Evaluation of FAK-Src-paxillin as biomarkers and therapeutic targets.

Main Results:

  • FAK-Src-paxillin complex overexpression is linked to advanced NB.
  • The complex plays a significant role in cell migration and motility.
  • Emerging data suggests potential as biomarkers and therapeutic targets.

Conclusions:

  • Combined inhibition of FAK-Src-Paxillin may suppress NB tumors.
  • Concurrent targeting could prevent or delay metastasis in NB patients.
Keywords:
Srcfocal adhesion kinaseneuroblastomapaxillinsmall-molecule inhibitors

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.7K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K